Recent economic research has examined potential killer acquisitions in the U.S., and regulators here and abroad have expressed competition concerns about acquisitions of startups. But innovation is a difficult and uncertain process. This panel explores hot topics, patent thickets, biologics, and the revamped UK CMA approach in a broader discussion of the renaissance of innovation theories of harm.

E. Bill BATCHELOR / Skadden Arps Slate Meagher & Flom LLP, Brussels

  • Deborah FEINSTEIN / Arnold & Porter, Washington, DC
  • W. Robert MAJURE / Cornerstone Research, Washington, DC
  • James R. WEISS / Deputy Assistant Director, Mergers I, Federal Trade Commission, Washington, DC